Toutes les photos(1)

Key Documents

COO/COA

View All Documentation

Y0000197

Ondansetron for LC system suitability

Name: Ondansetron for LC system suitability
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Ondansetron hydrochloride dihydrate, 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one hydrochloride, GR 38032F

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):

C₁₈H₁₉N₃O · HCl · 2H₂O

Numéro CAS:

103639-04-9

Poids moléculaire :

365.85

Numéro MDL:

MFCD00374371

Code UNSPSC :

41116107

ID de substance PubChem :

329830879

Nomenclature NACRES :

NA.24

Produits recommandés

Slide 1 of 10

1 of 10

Y0001320

Ondansetron impurity F

Y0001346

Ondansetron impurity G

Supelco

PHR1141

Ondansetron Hydrochloride

Sigma-Aldrich

O3639

Ondansetron hydrochloride dihydrate

USP

1478582

Ondansetron hydrochloride

USP

1478593

Ondansetron Related Compound A

Y0000218

Ondansetron hydrochloride dihydrate

Y0000196

Ondansetron for TLC system suitability

USP

1478630

Ondansetron Resolution Mixture

Y0001345

Ondansetron impurity A

Qualité

pharmaceutical primary standard

Famille d'API

ondansetron

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES

Cl[H].[H]O[H].[H]O[H].Cc1nccn1CC2CCc3c(C2=O)c4ccccc4n3C

InChI

1S/C18H19N3O.ClH.2H2O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2;;;/h3-6,9-10,13H,7-8,11H2,1-2H3;1H;2*1H2

Clé InChI

VRSLTNZJOUZKLX-UHFFFAOYSA-N

Informations sur le gène

human ... HTR3A(3359)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Étalons de référence analytiques | Sigma-Aldrich

Étalons des instituts de métrologie et des pharmacopées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ondansetron for LC system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

5-HT₃serotonin receptor antagonist

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit

Description

Tarif

PHR1141

Ondansetron Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

1478618

1478593

1478629

PHR2224

PHR2223

PHR2221

Pictogrammes

GHS06,GHS05,GHS09

Mention d'avertissement

Danger

Mentions de danger

H301,H318,H410

Conseils de prudence

P264 - P273 - P280 - P301 + P310 - P305 + P351 + P338 - P391

Classification des risques

Acute Tox. 3 Oral - Aquatic Acute 1 - Aquatic Chronic 2 - Eye Dam. 1

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Do children with high body mass indices have a higher incidence of emesis when undergoing ketamine sedation?

Kristi L Kinder et al.

Pediatric emergency care, 28(11), 1203-1205 (2012-11-02)

The objective of this study was to determine if overweight children are more likely than normal-weight children to require ondansetron when undergoing ketamine sedation in a pediatric emergency department. Patients between the ages of 2 and 18 years with an

Clinical and economic impact of oral ondansetron for vomiting in a pediatric emergency department.

Daniel Hervás et al.

Pediatric emergency care, 28(11), 1166-1168 (2012-11-02)

In this study, we determine the clinical impact of 1 dose of oral ondansetron for children with vomiting and evaluate the economic consequences of its use. The strategies compared were administering oral ondansetron in addition to oral rehydration therapy (group

Thiolated xyloglucan: Synthesis, characterization and evaluation as mucoadhesive in situ gelling agent.

Hitendra S Mahajan et al.

Carbohydrate polymers, 91(2), 618-625 (2012-11-06)

The objective of present study was to enhance bioadhesive potential of xyloglucan by thiolation. Thiolation of xyloglucan was achieved with esterification with thioglycolic acid. Thiolated xyloglucan was characterized by NMR, DSC, and XRD analysis. Thiolated xyloglucan was determined to possess

A pilot study of full-dose ondansetron to treat heavy-drinking men withdrawing from alcohol in Brazil.

João Maria Corrêa Filho et al.

Addictive behaviors, 38(4), 2044-2051 (2013-02-12)

Ondansetron has emerged as a promising medication for the treatment of alcohol dependence, mainly among early-onset alcoholics. This research primarily aimed to evaluate the efficacy and safety of ondansetron at a 16mg/day dosage to treat alcohol-dependent outpatients. A double-blind, placebo-controlled

Development of HPTLC method for the estimation of ondansetron hydrochloride in bulk drug and sublingual tablets.

Ali Mujtaba et al.

Drug testing and analysis, 5(2), 122-125 (2013-02-16)

A new, simple, rapid, accurate and precise high performance thin layer chromatography (HPTLC) method has been developed for the estimation of ondansetron hydrochloride in bulk and sublingual tablets. The mobile phase composition was chloroform : ethyl acetate : methanol :

Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique